I-Factor is just one of two FDA approved Class III drug-device bone grafts with a spinal indication, according to a July 19 press release.
By expanding its facility, Cerapedics is adding over 50 percent more space for manufacturing, research and development. It has hired more than 100 employees in the state in the last five years and plans to add another 60 by the end of 2024.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
